Akebia Therapeutics (AKBA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

AKBA Stock Forecast

Akebia Therapeutics stock forecast is as follows: an average price target of $6.50 (represents a 257.14% upside from AKBA’s last price of $1.82) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

AKBA Price Target

The average price target for Akebia Therapeutics (AKBA) is $6.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $6.00. This represents a potential 257.14% upside from AKBA's last price of $1.82.

AKBA Analyst Ratings

Buy

According to 5 Wall Street analysts, Akebia Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AKBA stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Akebia Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Mar 28, 2024	Ed Arce	H.C. Wainwright	$6.00	$1.98	203.03%	229.67%
Mar 03, 2022	Serge Belanger	Needham	$7.00	$2.65	164.15%	284.62%

Row per page

Go to

The latest Akebia Therapeutics stock forecast, released on Mar 28, 2024 by Ed Arce from H.C. Wainwright, set a price target of $6.00, which represents a 203.03% increase from the stock price at the time of the forecast ($1.98), and a 229.67% increase from AKBA last price ($1.82).

Akebia Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$6.00
Last Closing Price	$1.82	$1.82	$1.82
Upside/Downside	-100.00%	-100.00%	229.67%

In the current month, the average price target of Akebia Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Akebia Therapeutics's last price of $1.82. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 11, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 06, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 12, 2024	H.C. Wainwright	Buy	Buy	Hold
Mar 28, 2024	H.C. Wainwright	Buy	Buy	Hold
May 31, 2023	Seaport Global	-	Sector Weight	Downgrade
May 31, 2023	Piper Sandler	-	Overweight	Upgrade
Mar 03, 2022	Needham	Buy	Buy	Hold
Apr 29, 2021	Mizuho Securities	Buy	Buy	Hold

Row per page

Go to

Akebia Therapeutics's last stock rating was published by H.C. Wainwright on Oct 11, 2024. The company gave AKBA a "Buy" rating, the same as its previous rate.

Akebia Therapeutics Financial Forecast

Akebia Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$42.05M	$56.38M	$40.13M	$55.18M	$48.96M	$126.76M	$61.70M	$59.60M	$48.76M	$52.91M	$52.30M	$56.70M	$59.99M	$90.14M	$88.48M	$69.56M	$91.98M	$100.80M	$72.67M	$45.93M	$20.86M
Avg Forecast	$56.89M	$47.28M	$38.19M	$35.63M	$45.87M	$44.50M	$49.80M	$46.09M	$55.39M	$48.18M	$59.10M	$46.68M	$47.40M	$48.88M	$53.03M	$44.27M	$51.77M	$49.62M	$52.31M	$42.32M	$51.10M	$84.90M	$74.18M	$77.48M	$93.15M	$99.38M	$91.12M	$81.02M	$56.42M	$7.09M
High Forecast	$66.33M	$55.13M	$44.53M	$44.97M	$51.57M	$51.89M	$58.07M	$46.09M	$56.06M	$56.18M	$68.91M	$54.43M	$55.27M	$48.88M	$53.03M	$44.27M	$51.77M	$49.62M	$52.31M	$42.32M	$51.10M	$84.90M	$74.18M	$77.48M	$93.15M	$99.38M	$91.12M	$81.02M	$67.70M	$8.51M
Low Forecast	$46.18M	$38.38M	$31.00M	$26.29M	$40.17M	$36.12M	$40.43M	$46.09M	$54.73M	$39.11M	$47.98M	$37.90M	$38.48M	$48.88M	$53.03M	$44.27M	$51.77M	$49.62M	$52.31M	$42.32M	$51.10M	$84.90M	$74.18M	$77.48M	$93.15M	$99.38M	$91.12M	$81.02M	$45.13M	$5.67M
# Analysts	1	1	1	2	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	11
Surprise %	-	-	-	-	-	-	-	-	-	0.87%	0.95%	0.86%	1.16%	1.00%	2.39%	1.39%	1.15%	0.98%	1.01%	1.24%	1.11%	0.71%	1.22%	1.14%	0.75%	0.93%	1.11%	0.90%	0.81%	2.94%

Akebia Therapeutics's average Quarter revenue forecast for Dec 23 based on 2 analysts is $55.39M, with a low forecast of $54.73M, and a high forecast of $56.06M. AKBA's average Quarter revenue forecast represents a 31.74% increase compared to the company's last Quarter revenue of $42.05M (Sep 23).

Akebia Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	11
EBITDA	-	-	-	-	-	-	-	-	-	$-3.50M	$-8.66M	$-24.73M	$-3.91M	$-37.40M	$58.27M	$-47.93M	$-66.31M	$-44.98M	$-68.57M	$-55.25M	$-81.59M	$-51.06M	$-163.82M	$-49.15M	$-87.34M	$-45.90M	$-48.84M	$-64.77M	$-22.14M	$-43.97M
Avg Forecast	$-33.25M	$-27.64M	$-22.32M	$-20.83M	$-26.81M	$-26.01M	$-29.11M	$-46.00M	$-32.38M	$-28.16M	$-34.54M	$-41.82M	$-47.96M	$-29.67M	$-32.19M	$-38.01M	$-31.42M	$-30.12M	$-31.75M	$-27.24M	$-31.02M	$-51.53M	$-45.03M	$-63.49M	$-56.54M	$-60.31M	$-55.30M	$-32.49M	$-27.55M	$-42.13M
High Forecast	$-26.99M	$-22.43M	$-18.12M	$-15.37M	$-23.48M	$-21.11M	$-23.63M	$-36.80M	$-31.99M	$-22.86M	$-28.04M	$-33.45M	$-38.37M	$-29.67M	$-32.19M	$-30.41M	$-31.42M	$-30.12M	$-31.75M	$-21.80M	$-31.02M	$-51.53M	$-45.03M	$-50.79M	$-56.54M	$-60.31M	$-55.30M	$-25.99M	$-22.04M	$-33.70M
Low Forecast	$-38.77M	$-32.22M	$-26.03M	$-26.29M	$-30.14M	$-30.33M	$-33.94M	$-55.20M	$-32.77M	$-32.84M	$-40.28M	$-50.18M	$-57.55M	$-29.67M	$-32.19M	$-45.62M	$-31.42M	$-30.12M	$-31.75M	$-32.69M	$-31.02M	$-51.53M	$-45.03M	$-76.19M	$-56.54M	$-60.31M	$-55.30M	$-38.99M	$-33.06M	$-50.56M
Surprise %	-	-	-	-	-	-	-	-	-	0.12%	0.25%	0.59%	0.08%	1.26%	-1.81%	1.26%	2.11%	1.49%	2.16%	2.03%	2.63%	0.99%	3.64%	0.77%	1.54%	0.76%	0.88%	1.99%	0.80%	1.04%

1 analysts predict AKBA's average Quarter EBITDA for Sep 22 to be $-29.67M, with a high of $-29.67M and a low of $-29.67M. This is -150.91% lower than Akebia Therapeutics's previous annual EBITDA (Jun 22) of $58.27M.

Akebia Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	11
Net Income	-	-	-	-	-	-	-	-	-	$-14.49M	$-11.17M	$-16.74M	$-8.76M	$-55.74M	$29.28M	$-66.35M	$-65.59M	$-59.54M	$-83.04M	$-69.58M	$-87.00M	$-59.96M	$-175.75M	$-60.75M	$-94.48M	$-54.59M	$-58.17M	$-72.42M	$-23.42M	$-44.54M
Avg Forecast	$-5.61M	$-11.22M	$-18.93M	$-17.53M	$-14.72M	$-13.32M	$-15.20M	$-59.90M	$-8.06M	$-17.88M	$-5.26M	$-54.46M	$-52.63M	$-35.65M	$-67.80M	$-49.51M	$-63.96M	$-67.11M	$-71.11M	$-34.31M	$-83.28M	$-35.39M	$-100.66M	$-75.44M	$-99.09M	$-89.27M	$-67.37M	$-35.85M	$-27.78M	$-42.26M
High Forecast	$-4.24M	$-8.47M	$-14.30M	$-13.24M	$-11.12M	$-10.06M	$-11.48M	$-47.92M	$-4.84M	$-13.50M	$-3.97M	$-43.57M	$-42.11M	$-35.65M	$-67.80M	$-39.61M	$-63.96M	$-67.11M	$-71.11M	$-27.45M	$-83.28M	$-35.39M	$-100.66M	$-60.36M	$-99.09M	$-89.27M	$-67.37M	$-28.68M	$-22.23M	$-33.81M
Low Forecast	$-6.82M	$-13.64M	$-23.02M	$-21.31M	$-17.90M	$-16.20M	$-18.48M	$-71.88M	$-9.68M	$-21.74M	$-6.39M	$-65.35M	$-63.16M	$-35.65M	$-67.80M	$-59.41M	$-63.96M	$-67.11M	$-71.11M	$-41.17M	$-83.28M	$-35.39M	$-100.66M	$-90.53M	$-99.09M	$-89.27M	$-67.37M	$-43.02M	$-33.34M	$-50.71M
Surprise %	-	-	-	-	-	-	-	-	-	0.81%	2.12%	0.31%	0.17%	1.56%	-0.43%	1.34%	1.03%	0.89%	1.17%	2.03%	1.04%	1.69%	1.75%	0.81%	0.95%	0.61%	0.86%	2.02%	0.84%	1.05%

Akebia Therapeutics's average Quarter net income forecast for Sep 22 is $-35.65M, with a range of $-35.65M to $-35.65M. AKBA's average Quarter net income forecast represents a -221.77% decrease compared to the company's last Quarter net income of $29.28M (Jun 22).

Akebia Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	11
SG&A	-	-	-	-	-	-	-	-	-	$22.71M	$27.04M	$25.22M	$31.50M	$31.66M	$33.70M	$45.02M	$45.85M	$47.23M	$42.55M	$42.02M	$41.29M	$40.88M	$36.53M	$38.66M	$45.89M	$35.11M	$36.96M	$35.03M	$9.02M	$5.79M
Avg Forecast	$31.66M	$26.32M	$21.26M	$19.83M	$25.53M	$24.77M	$27.72M	$43.20M	$30.83M	$26.82M	$32.89M	$39.27M	$24.98M	$27.37M	$29.69M	$35.70M	$28.98M	$27.78M	$29.29M	$20.72M	$28.61M	$47.53M	$41.53M	$48.01M	$52.15M	$55.64M	$51.02M	$17.34M	$10.71M	$5.49M
High Forecast	$36.92M	$30.68M	$24.78M	$25.03M	$28.70M	$28.88M	$32.32M	$51.84M	$31.20M	$31.27M	$38.35M	$47.13M	$29.98M	$27.37M	$29.69M	$42.84M	$28.98M	$27.78M	$29.29M	$24.87M	$28.61M	$47.53M	$41.53M	$57.61M	$52.15M	$55.64M	$51.02M	$20.81M	$12.85M	$6.59M
Low Forecast	$25.70M	$21.36M	$17.26M	$14.63M	$22.35M	$20.11M	$22.50M	$34.56M	$30.46M	$21.77M	$26.70M	$31.42M	$19.98M	$27.37M	$29.69M	$28.56M	$28.98M	$27.78M	$29.29M	$16.58M	$28.61M	$47.53M	$41.53M	$38.41M	$52.15M	$55.64M	$51.02M	$13.87M	$8.57M	$4.39M
Surprise %	-	-	-	-	-	-	-	-	-	0.85%	0.82%	0.64%	1.26%	1.16%	1.14%	1.26%	1.58%	1.70%	1.45%	2.03%	1.44%	0.86%	0.88%	0.81%	0.88%	0.63%	0.72%	2.02%	0.84%	1.05%

Akebia Therapeutics's average Quarter SG&A projection for Dec 23 is $30.83M, based on 2 Wall Street analysts, with a range of $30.46M to $31.20M. The forecast indicates a 35.75% rise compared to AKBA last annual SG&A of $22.71M (Sep 23).

Akebia Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	11
EPS	-	-	-	-	-	-	-	-	-	$-0.08	$-0.06	$-0.09	$-0.05	$-0.30	$0.16	$-0.37	$-0.37	$-0.34	$-0.51	$-0.45	$-0.60	$-0.42	$-1.28	$-0.47	$-0.79	$-0.46	$-0.49	$-0.62	$-0.48	$-1.15
Avg Forecast	$-0.03	$-0.05	$-0.09	$-0.08	$-0.07	$-0.06	$-0.07	$-0.07	$-0.04	$-0.09	$-0.03	$-0.14	$-0.18	$-0.17	$-0.32	$-0.29	$-0.30	$-0.32	$-0.34	$-0.37	$-0.40	$-0.17	$-0.48	$-0.62	$-0.47	$-0.43	$-0.32	$-0.40	$-0.70	$-0.37
High Forecast	$-0.02	$-0.04	$-0.07	$-0.06	$-0.05	$-0.05	$-0.05	$-0.05	$-0.02	$-0.06	$-0.02	$-0.11	$-0.14	$-0.17	$-0.32	$-0.29	$-0.30	$-0.32	$-0.34	$-0.37	$-0.40	$-0.17	$-0.48	$-0.62	$-0.47	$-0.43	$-0.32	$-0.40	$-0.56	$-0.30
Low Forecast	$-0.03	$-0.06	$-0.11	$-0.10	$-0.09	$-0.08	$-0.09	$-0.09	$-0.05	$-0.10	$-0.03	$-0.18	$-0.22	$-0.17	$-0.32	$-0.29	$-0.30	$-0.32	$-0.34	$-0.37	$-0.40	$-0.17	$-0.48	$-0.62	$-0.47	$-0.43	$-0.32	$-0.40	$-0.84	$-0.44
Surprise %	-	-	-	-	-	-	-	-	-	0.90%	2.39%	0.62%	0.26%	1.76%	-0.49%	1.29%	1.21%	1.06%	1.50%	1.22%	1.51%	2.49%	2.67%	0.76%	1.67%	1.08%	1.53%	1.55%	0.69%	3.11%

According to 1 Wall Street analysts, Akebia Therapeutics's projected average Quarter EPS for Sep 22 is $-0.17, with a low estimate of $-0.17 and a high estimate of $-0.17. This represents a -206.25% decrease compared to AKBA previous annual EPS of $0.16 (Jun 22).

Akebia Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.69	$70.00	10044.93%	Buy
ELEV	Elevation Oncology	$0.61	$9.00	1375.41%	Buy
XFOR	X4 Pharmaceuticals	$0.37	$3.67	891.89%	Buy
AKBA	Akebia Therapeutics	$1.82	$6.50	257.14%	Buy
MCRB	Seres Therapeutics	$0.73	$1.25	71.23%	Buy
CDTX	Cidara Therapeutics	$17.45	$24.00	37.54%	Buy

AKBA Forecast FAQ

Is Akebia Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Akebia Therapeutics (AKBA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of AKBA's total ratings.

What is AKBA's price target?

Akebia Therapeutics (AKBA) average price target is $6.5 with a range of $6 to $7, implying a 257.14% from its last price of $1.82. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Akebia Therapeutics stock go up soon?

According to Wall Street analysts' prediction for AKBA stock, the company can go up by 257.14% (from the last price of $1.82 to the average price target of $6.5), up by 284.62% based on the highest stock price target, and up by 229.67% based on the lowest stock price target.

Can Akebia Therapeutics stock reach $3?

AKBA's average twelve months analyst stock price target of $6.5 supports the claim that Akebia Therapeutics can reach $3 in the near future.

What are Akebia Therapeutics's analysts' financial forecasts?

Akebia Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $186.26M (high $207.62M, low $162.81M), average EBITDA is $-128M (high $-105M, low $-150M), average net income is $-103M (high $-80.585M, low $-124M), average SG&A $121.21M (high $141.74M, low $99.52M), and average EPS is $-0.278 (high $-0.21, low $-0.337). AKBA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $177.99M (high $210.97M, low $141.86M), average EBITDA is $-104M (high $-82.911M, low $-123M), average net income is $-53.288M (high $-40.25M, low $-64.788M), average SG&A $99.06M (high $117.41M, low $78.95M), and average EPS is $-0.253 (high $-0.191, low $-0.308).

Did the AKBA's actual financial results beat the analysts' financial forecasts?

Based on Akebia Therapeutics's last annual report (Dec 2023), the company's revenue was $194.62M, which missed the average analysts forecast of $209.36M by -7.04%. Apple's EBITDA was $-46.256M, missing the average prediction of $-137M by -66.21%. The company's net income was $-51.925M, missing the average estimation of $-85.659M by -39.38%. Apple's SG&A was $100.23M, missing the average forecast of $129.81M by -22.78%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-0.293 by -99.90%. In terms of the last quarterly report (Sep 2023), Akebia Therapeutics's revenue was $42.05M, missing the average analysts' forecast of $48.18M by -12.74%. The company's EBITDA was $-3.503M, missing the average prediction of $-28.162M by -87.56%. Akebia Therapeutics's net income was $-14.489M, missing the average estimation of $-17.88M by -18.96%. The company's SG&A was $22.71M, missing the average forecast of $26.82M by -15.31%. Lastly, the company's EPS was $-0.0769, missing the average prediction of $-0.085 by -9.53%